文献速递头颈外科

高剂量率介入放疗(近距离放疗)治疗原发性和复发性头颈部恶性肿瘤

HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies.
PubMed 文献 · Head Neck · 2019-01-30

对58例患者共61次高剂量率介入放疗(HDR IRT)进行分组评估,按临床需求分为四组并区分初治与复发。四组疾病特异性生存差异显著,预后最佳者为可切除面中部恶性肿瘤行单纯间质IRT组,2年无复发生存率82%、疾病特异性生存率89%。作者认为HDR IRT在界定明确的临床情形尤其复发者中有价值,面中部恶性肿瘤中或可成为首选初治手段。

要点

  • 58例患者共接受61次HDR IRT,按临床需求分为四组并区分原发与复发。
  • 四组间疾病特异性生存差异显著,预后最佳组2年无复发生存率82%、疾病特异性生存率89%。
  • 作者认为HDR IRT在复发等界定明确情形中有价值,面中部恶性肿瘤或可作首选初治。

核心结论

  • 作者认为HDR IRT在界定明确的临床情形中有价值,尤其在复发者中。
  • 作者认为在面中部恶性肿瘤中,HDR IRT或可成为首选的初治手段。

研究设计与样本

  • 对58例患者共61次HDR IRT治疗进行分组评估。
  • 按导致推荐IRT的临床需求将病例分为四个相对同质的组。
  • 分别评估原发病例与复发病例。

主要发现

  • 四组间疾病特异性生存存在显著差异。
  • 预后最佳组为可切除面中部恶性肿瘤行单纯间质IRT局部治疗组,2年无复发生存率82%、疾病特异性生存率89%。

关键数值与推荐

  • 可切除面中部恶性肿瘤行单纯间质IRT组:2年无复发生存率82%,疾病特异性生存率89%。

临床怎么用

  • 作者认为HDR IRT在界定明确的临床情形中有价值,尤其在复发者中。
  • 作者认为在面中部恶性肿瘤中HDR IRT或可成为首选的初治手段。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interventional radiotherapy (brachytherapy; IRT) reemerged in the last decades as a potentially useful tool in head and neck oncology after a set of clear technical improvements were developed. METHODS: Sixty-one high dose ratio (HDR) IRT treatments were recommended and performed on 58 patients. We classified the cases into four relatively homogeneous groups based on the clinical needs that led to the recommended IRT. Also, we separately evaluated primary and recurrent cases. RESULTS: Disease-specific survival was significantly different among the four treatment groups. The group with the best prognosis was the cohort treated locally by exclusive interstitial IRT for resectable midface malignancies (2-year relapse-free survival = 82%, disease-specific survival = 89%). CONCLUSION: HDR IRT is a valuable tool in well-defined clinical situations and, in particular, in recurrences. In midface malignancies, it could become the preferred primary treatment.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Bussu F, Tagliaferri L, Mattiucci G, et al. HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies. Head Neck. 2019. PMID: 30701614. doi:10.1002/hed.25646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。